---
layout: page
title: >-
  IBD Stock Of The Day Nears Profitability As Revenue Spikes
image: /assets/img/stock-of-the-day/2018-12-18.jpg
date: 2018-12-18 16:11 -0800
author: ALLISON GATLIN
---






**CareDx** ([CDNA](https://research.investors.com/quote.aspx?symbol=CDNA)) is the [IBD Stock Of The Day](https://www.investors.com/research/ibd-stock-of-the-day/) as the diagnostics stock approaches its first quarter in the black amid continuing sales growth.




On the [stock market today](https://www.investors.com/market-trend/stock-market-today/stock-market-today-market-trends-best-stocks-buy-watch/), CareDx [stock](https://www.investors.com/research/stock-market-data-dow-jones-sp-500-nasdaq-spdr-etfs/) rose 4.6%, to 25.51. Shares haven't formed a specific chart pattern, but are trading in a tight range, a positive sign in a tough market.


Diagnostic Test For Transplants
-------------------------------





IBD Newsletters
---------------


#### Get exclusive IBD analysis and actionable news daily.




SIGN UP NOW!





IBD Newsletters
---------------


#### Get exclusive IBD analysis and actionable news daily.




* Financial Advisor Update
* How To Invest
* Market Prep
* Tech Report



Please enter a valid email address
Please select a newsletter


GO
Get these newsletters delivered to your inbox & more info about our products & services. [Privacy Policy](https://www.investors.com/investors-business-daily-privacy-policy/) & [Terms of Use](https://www.investors.com/home/investors-business-daily-inc-terms-of-use/)



x



Thank You!
----------


#### You will now receive IBD Newsletters




ALL DONE!




Something Went Wrong!
---------------------


#### Please contact customer service




CLOSE




CareDx makes diagnostic tests for patients who've received a heart transplant or kidney transplant. These tests determine if the body is accepting or rejecting the transplant.


Sales were particularly strong in the quarter ended in September. CareDx reported $21.2 million in sales, which spiked 74% year over year. CareDx's sales have grown by a double-digit percentages for four quarters.


Analysts expect CareDx to make a repeat of its prior quarter performance. Analysts polled by Thomson Reuters call for CareDx to report sales gains of 74%, 66%, 40% and 24% in the next four periods.


Meanwhile, CareDx looks to gain profitability next year starting with a 1 cent per-share profit in the first /quarter. For the coming year, the Street projects 14 cents.


CareDx Stock Is Turning Heads
-----------------------------


CareDx stock is also grabbing some interest from mutual funds. Alger Small-Cap Focus Fund ([AOFAX](https://research.investors.com/quote.aspx?symbol=AOFAX)), one of the top-ranked funds in its category by Morningstar Direct, has been steadily buying shares of CareDx stock over the past several quarters. The Alger fund gets a five-star rating from Morningstar and an A+ rating from Investor's Business Daily.



Over the past 12 months, CareDx stock has accrued an IBD [Relative Strength Rating](https://www.investors.com/research/best-stocks-rising-relative-strength/) of 99, meaning it performs in the top 1% of all stocks in terms of price performance. Four stocks in the medical-products industry group have RS Ratings of 99.


CareDx stock also has a [Composite Rating](https://www.investors.com/how-to-invest/investors-corner/the-ibd-composite-rating/) of 93, out of a best-possible 99. The CR tracks key growth metrics for each stock.


**YOU MIGHT ALSO LIKE:**


[What Is Inflation, And Why Does It Matter To The Fed â€” And You?](https://www.investors.com/news/economy/what-is-inflation-what-causes-inflation/)


[Long-Term Retirement Investment Strategies With ETFs](https://www.investors.com/etfs-and-funds/etfs/retirement-investing-strategies-etfs-for-the-long-term/)


[How Much Money Do You Need To Start Investing In Stocks?](https://www.investors.com/how-to-invest/investors-corner/how-much-money-do-you-need-to-start-investing/)




